NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody

Conditions:   Head and Neck Cancer;   NSCLC;   Radiotherapy;   Immunotherapy
Intervention:   Drug: NBTXR3
Sponsor:   Nanobiotix
Not yet recruiting

https://ift.tt/2mtBt8p